

JPET # 265538

## Title Page

# **Parsaclisib Is a Next-Generation PI3K $\delta$ Inhibitor With Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy<sup>a</sup>**

Niu Shin, Matthew Stubbs, Holly Koblish, Eddy W. Yue, Maxim Soloviev, Brent Douty, Kathy He Wang, Qian Wang, Mingming Gao, Patricia Feldman, Gengjie Yang, Leslie Hall, Michael Hansbury, Sybil O'Connor, Lynn Leffet, Robert Collins, Kamna Katiyar, Xin He, Paul Waeltz, Paul Collier, Jin Lu, Yun-Long Li, Yanlong Li, Phillip C.C. Liu<sup>1</sup>, Timothy Burn, Maryanne Covington, Sharon Diamond, Dana Shuey, Alan Roberts, Swamy Yeleswaram, Greg Hollis, Brian Metcalf<sup>1</sup>, Wenqing Yao, Reid Huber<sup>1</sup>, Andrew Combs<sup>1</sup>, Robert Newton, and Peggy Scherle<sup>1</sup>

*Incyte Research Institute, Wilmington, Delaware*

JPET # 265538

## Running Title Page

**Running Title:** Preclinical Characterization of PI3K $\delta$  Inhibitor Parsaclisib

**Address correspondence to:** Niu Shin, Incyte Research Institute, Incyte Corporation, 1801  
Augustine Cut Off, Wilmington, DE 19803. Phone: 302-498-6810; Fax: +1-302-425-2750; E-  
mail: nshin@incyte.com

Text pages: 28 pages

No. of tables: 1

No. of figures: 5

No. of references: 47

Abstract word count: 220

Introduction word count: 591

Discussion word count: 1484

**ABBREVIATIONS:** BET, bromodomain and extraterminal protein; B-cell receptor; CCL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GLP, Good Laboratory Practice; MCL, mantle cell lymphoma; ORR, overall response rates; PI3K, phosphoinositide 3-kinase; TGI, tumor growth inhibition; Treg, regulatory T cell.

**Section assignment:** Drug Discovery and Translational Medicine

JPET # 265538

## ABSTRACT

The clinical use of first-generation phosphoinositide 3-kinase (PI3K) $\delta$  inhibitors in B-cell malignancies is hampered by hepatotoxicity, requiring dose reduction, treatment interruption, and/or discontinuation of therapy. In addition, potential molecular mechanisms by which resistance to this class of drugs occurs have not been investigated. Parsaclisib (INCB050465) is a potent and selective next-generation PI3K $\delta$  inhibitor that differs in structure from first-generation PI3K $\delta$  inhibitors and has shown encouraging anti-B-cell tumor activity and reduced hepatotoxicity in phase 1/2 clinical studies. Here, we present preclinical data demonstrating parsaclisib as a potent inhibitor of PI3K $\delta$  with over 1000-fold selectivity against other class 1 PI3K isozymes. Parsaclisib directly blocks PI3K signaling-mediated cell proliferation in B-cell lines in vitro and in vivo, and indirectly controls tumor growth by lessening immunosuppression through regulatory T-cell inhibition in a syngeneic lymphoma model. Diffuse large B-cell lymphoma cell lines overexpressing MYC were insensitive to proliferation blockade via PI3K $\delta$  signaling inhibition by parsaclisib, but their proliferative activities were reduced by suppression of MYC gene transcription. Molecular structure analysis of the first- and next-generation PI3K $\delta$  inhibitors combined with clinical observation suggest that hepatotoxicity seen with the first-generation inhibitors could result from a structure-related off-target effect. Parsaclisib is currently being evaluated in multiple phase 2 clinical trials as a therapy against various hematologic malignancies of B-cell origin (NCT03126019, NCT02998476, NCT03235544, NCT03144674, and NCT02018861).

JPET # 265538

## **SIGNIFICANCE STATEMENT**

The preclinical properties described here provide the mechanism of action and support clinical investigations of parsacalisib as a therapy for B-cell malignancies. MYC overexpression was identified as a resistance mechanism to parsacalisib in DLBCL cells, which may be useful in guiding further translational studies for the selection of patients with DLBCL who might benefit from PI3K $\delta$  inhibitor treatment in future trials. Hepatotoxicity associated with first-generation PI3K $\delta$  inhibitors may be an off-target effect of that class of compounds.

## INTRODUCTION

The phosphoinositide 3-kinases (PI3Ks) regulate diverse biological functions by generating lipid second messengers. PI3K $\delta$  is the main isozyme responsible for the activation of the PI3K pathway in B-cell biology, functioning as a downstream mediator of the B-cell receptor (BCR), Toll-like receptors, and cytokine receptors (Puri and Gold, 2012). Because of the linkage of these signaling pathways to cancer biology, multiple drug discovery efforts to identify PI3K $\delta$  inhibitors for treating B-cell malignancies have been initiated (Greenwell et al., 2017). Inhibitors that are selective for PI3K $\delta$  versus other class I PI3K isoforms possess the advantage of avoiding toxicities that result from, for example, disruption of insulin signaling (PI3K $\alpha$ ) and spermatogenesis (PI3K $\beta$ ) (Hers, 2007; Ciraolo et al., 2010). Idelalisib, a first-generation PI3K $\delta$ -selective inhibitor, is approved for the treatment of chronic and relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and follicular lymphoma (FL). Copanlisib, a pan-PI3K inhibitor with primary activity against  $\alpha$  and  $\delta$  isoforms, and duvelisib, a PI3K $\delta/\gamma$  dual inhibitor, were recently approved for FL and CLL/small lymphocytic lymphoma or FL, respectively. Several other PI3K $\delta$  inhibitors are at different stages of clinical development for B-cell-related diseases.

Clinical toxicities have hindered development of first-generation PI3K $\delta$ -selective inhibitors, such as idelalisib and duvelisib. Hepatotoxicity is one of the most common adverse events, which, in the case of idelalisib, has led to dose reduction and treatment discontinuation (Coutr  et al., 2015). Therefore, there is an unmet need for a PI3K $\delta$  inhibitor with an improved safety profile, including minimal hepatotoxicity, as well as potent antitumor activity.

Idelalisib may cause hepatotoxicity by immune activation, since peripheral blood regulatory T cells (Tregs) were seen in patients experiencing hepatotoxicity while receiving

JPET # 265538

idelalisib treatment (Lampson et al., 2016). Based on this hypothesis, hepatotoxicity would be predicted to be a class effect of PI3K $\delta$  inhibition. However, the possibility remained that idelalisib treatment–induced hepatotoxicity could result from an off-target effect derived from its molecular structure. Thus, we initiated a discovery program for a next-generation PI3K $\delta$  inhibitor that differed in chemical structure from those of the first-generation compounds, including idelalisib. Parsaclisib (INCB050465) is a product of this discovery effort (Yue et al., 2019).

Parsaclisib is currently in phase 2 clinical trials as a therapy against various hematologic malignancies of B-cell origin. In a recent phase 1/2 study (Forero-Torres et al., 2019), parsaclisib monotherapy exhibited high overall response rates (ORRs) in patients with relapsed or refractory mantle cell lymphoma (MCL) (ORR 67%), FL (ORR 71%), and marginal zone lymphoma (ORR 78%), with lower responses observed in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL; 30%) and CLL (33%). Most responses (93%) occurred at first assessment (~9 weeks). Importantly, about 10-fold reduced hepatotoxicity (measured in alanine aminotransferase/aspartate aminotransferase elevation  $\geq$  grade 3) compared with first-generation PI3K $\delta$ -selective inhibitors was reported in this study (Forero-Torres et al., 2019).

This study reports the mechanism of action of the antitumor activity of parsaclisib, which targets PI3K-mediated proliferative signaling in malignant B cells and lessens immunosuppression in the tumor microenvironment. These data suggest that *MYC* oncogene overexpression may be a mechanism by which resistance to PI3K $\delta$  inhibition by parsaclisib occurs in some DLBCL cell lines. In addition, based on structure analysis and clinical study results, a new hypothesis is proposed for the hepatotoxicity commonly seen in the first-generation PI3K $\delta$  inhibitors. These results not only provide mechanistic support for the ongoing

JPET # 265538

clinical phase 2 studies of piasclisib for treating different B-cell malignancies, but may also be useful in guiding further translational studies for the selection of patients with DLBCL who might benefit from PI3K $\delta$  inhibitor treatment in future trials.

## MATERIALS AND METHODS

**Chemicals, Antibodies, and Cell Lines.** Parsaclisib and INCB054329 were synthesized at Incyte Corporation (Wilmington, Delaware). Supplier information for chemicals, antibodies, and cell lines used in the study is provided in the Supplementary Methods. All cell lines were maintained according to the instructions from suppliers.

**Biochemical Assays.** The detailed protocols for measuring biochemical activity of class 1 PI3K isozymes and 57 other kinases on the Incyte internal kinase panel have been described previously (Shin et al., 2018). The non-Good Laboratory Practice (GLP) General Side Effect PROFILE II screen at 0.1 and 1  $\mu\text{M}$  of parsaclisib in 70 in vitro binding or enzyme assays and the non-GLP PerkinElmer Discovery Services Kinase Assay screen of 192 kinases at 0.1  $\mu\text{M}$  of parsaclisib were evaluated by Caliper Life Sciences (Hanover, Maryland).

**In Vitro Assays.** The detailed protocol for Western blotting used to measure platelet-derived growth factor, lysophosphatidic acid, C5a, and anti-IgM-induced pAKT in NIH3T3, PC3, RAW264.7, and Ramos cells, respectively, was described previously (Shin et al., 2018). For measuring anti-IgM-induced pAKT in Ramos cells and C5a-induced pAKT in RAW264.7 cells, the cells were first serum starved in 0.2% fetal bovine serum overnight, followed by treatment with parsaclisib for 2 hours, and then stimulated with anti-IgM (4  $\mu\text{g}/\text{ml}$ ) or C5a (10  $\mu\text{g}/\text{ml}$ ) for 10 minutes at 37°C. After fixation, the Ramos cells were stained with the anti-pAKT (Ser473)-Fluor 488 antibody and analyzed by fluorescence-activated cell sorting according to the antibody supplier's recommended protocol; the RAW264.7 cells were stained with an anti-pAKT (Ser473) antibody and analyzed with In-Cell Western analysis using the Odyssey CLx imaging system (Li-COR, Lincoln, Nebraska) as per manufacturer's instruction. The constitutive level of pAKT in SKOV-3 and PC3-1 in the presence (2 hours) or absence of different concentrations of



JPET # 265538

paracalisib was measured by staining the cells with an anti-pAKT (Ser473) antibody followed by In-Cell Western analysis. The detailed procedures for purifying primary immune cells from different animal species, measuring proliferation of lymphoma cell lines and primary immune cells, differentiation of Th1, Th2, Th17 cells, cytokine production from human memory T cells and natural killer cells, anti-FcεR antibody-induced CD63 expression on basophils in the presence of human whole blood, and constitutive PI3K signaling in various lymphoma cell lines were described recently (Shin et al., 2018).

**Animal Models.** Non-GLP studies intended to characterize the pharmacology of paracalisib were conducted in accordance with Incyte Corporation's Institutional Animal Care and Use Committee-approved Animal Use Protocols. Animals were housed in barrier facilities fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. All procedures were conducted under the supervision of a veterinarian and in accordance with the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals.

For xenograft studies,  $1 \times 10^7$  cells (WILL-2, Rec-1) were resuspended in matrigel (BD Biosciences, Franklin Lakes, New Jersey) and injected subcutaneously into the dorsal flanks of severe combined immunodeficient mice (CB17/Icr-Prkdc scid/IcrIco Crl, Charles River Laboratories, Wilmington, Massachusetts). For the Pfeiffer model, subcutaneous tumors were grown to approximately  $1000 \text{ mm}^3$ , harvested, cut into fragments of approximately  $100 \text{ mm}^3$ , and then re-implanted subcutaneously into flanks of recipient mice. This results in more consistent tumor growth take-rates and kinetics. Subcutaneous tumors were allowed to grow until they reached approximately  $200 \text{ mm}^3$ , and the mice were randomized into dosing groups. For tumor growth studies, tumors were measured at least twice weekly with electronic calipers.

JPET # 265538

Tumor volumes were calculated using the formula:  $\text{volume} = (\text{length} \times \text{width}^2)/2$ , where width was the smaller dimension. Body weights were also monitored. For Western analyses of tumors, 1 g of tissue was homogenized with a hand-held homogenizer in 15 ml Cell Lysis Buffer (Cell Signaling Technology, Danvers, Massachusetts) with Complete Mini EDTA-free protease inhibitor cocktail (Sigma, St. Louis, Missouri), including phenylmethanesulfonyl fluoride (1 mM) and sodium orthovanadate (2 mM). Statistical significance was determined by Student's *t* test or 2-way analysis of variance using GraphPad Prism (La Jolla, California) software.

Gene expression in tumor samples was assessed by RNAseq. Total RNA from frozen tissue samples was isolated using an RNeasy Mini Kit (Qiagen, Germantown, Maryland) in a QIAcube (Qiagen, Hilden, Germany) according to the manufacturer's instructions. An optional DNase I digestion was performed. Sequencing was performed by BGI Americas (Cambridge, Massachusetts) on an Illumina Hi-seq4000 (San Diego, California). Raw RNA-seq fastq files were mapped to both human and mouse genome hg38. Clean human versions of gene transcripts were processed and quantified using OmicSoft ArrayStudio from Qiagen for further analyses. A general linear model for variant analysis was implemented in ArrayStudio. Gene Set Enrichment Analysis package was downloaded from the Broad Institute (Boston, Massachusetts).

For the syngeneic A20 lymphoma model, female Balb/c mice (5–9 weeks of age; Charles River Laboratories) were inoculated with A20 cells. A cell suspension in Hanks' balanced salt solution ( $1 \times 10^7$  cells/ml) was mixed 1:1 with matrigel, and 200  $\mu\text{l}$  was injected subcutaneously into the flank of each mouse. The treatment of the tumor-bearing mice started 7 to 24 days after tumor inoculation for efficacy studies. Mice were sorted to obtain approximately equivalent mean tumor volumes in each group. The starting mean tumor volume in efficacy studies for all groups ranged from 158 to 249  $\text{mm}^3$ , and groups consisted of 8 or 9 animals. Parsaclisib was

JPET # 265538

administered by oral gavage b.i.d. for 7 to 19 days (suspension in 5% dimethylacetamide with 0.5% w/v methylcellulose). For the statistical significance analysis, unpaired *t* test with Mann-Whitney post-test of tumor dimensions was performed with GraphPad Prism v.7.

To evaluate pharmacodynamics of pascalisib in the A20 model, mice were euthanized after 7 days of dosing, their tumors and spleens were excised (2 hours after final dose) and collected into RPMI media (Gibco, Gaithersburg, Maryland). Tumors were coarsely minced then processed to single-cell suspension by GentleMacs and Mouse Tumor Dissociation enzyme mix (Miltenyi, Sunnyvale, California) per the manufacturer's protocol. Spleens were diced and passed through Falcon mesh cell strainers (Fisher Scientific, Pittsburgh, Pennsylvania), red blood cells lysed with Pharm Lyse (BD Biosciences), then washed in phosphate-buffered saline. All single cell suspensions were resuspended in staining buffer (BD Biosciences) at  $1 \times 10^8$ /ml. The cells were treated with Fc block (BD Biosciences) for 5 minutes to reduce nonspecific bindings of antibodies to Fc receptors on cells and then stained with antibodies as described in the text, followed by fluorescence-activated cell sorting analysis.

Pascalisib was evaluated in GLP 28-day oral gavage toxicology studies in Sprague Dawley rats (15/sex/group) at dosages of 0, 10, 30, or 100 mg/kg/day, and Beagle dogs at 0, 1, 3, or 15 mg/kg/day, which included a 4-week recovery period, according to a standard protocol.

## RESULTS

**Parsaclisib Is a Highly Potent and Selective PI3K $\delta$  Inhibitor.** Parsaclisib ((R)-4(3-((S)-1-(4-amino-3-methyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one) (Fig. 1A) resulted from our efforts to identify a potent, selective, and structurally diverse PI3K $\delta$  inhibitor (Yue et al., 2019). In biochemical assays, parsaclisib potently inhibited PI3K $\delta$  activity ( $IC_{50} = 1$  nM), and was at least 1000-fold more selective for PI3K $\delta$  compared with the other 3 members of the class 1 PI3Ks (PI3K $\alpha$ , PI3K $\beta$ , and PI3K $\gamma$ ) (Fig. 1B). The selectivity of parsaclisib was further evaluated using a general side effect profile screen, conducted by Caliper Life Sciences (Hopkinton, Massachusetts). The results showed no interactions with 70 different channels and transporters and demonstrated little or no inhibition ( $\leq 15\%$  inhibition) of 192 kinases screened (data not shown).

In a cell-based assay, parsaclisib was active in suppressing PI3K $\delta$  signaling as measured by its inhibitory effect on anti-IgM-induced pAKT (Ser473) in the Ramos Burkitt's lymphoma cell line with an average  $IC_{50}$  value of approximately 1 nM (Fig. 1C and D). Consistent with the enzyme assay results, parsaclisib was much less active against PI3K $\alpha$ - and PI3K $\gamma$ -mediated signaling.  $IC_{50}$  values were  $>1000$  nM for the inhibition of PI3K $\alpha$  by parsaclisib, assessed based on platelet-derived growth factor-induced pAKT (Ser473) in NIH3T3 fibroblasts and constitutive pAKT (Ser473) in the SKOV-3 cells (Whyte and Holbeck, 2006; Lannutti et al., 2011), and  $>1000$  nM for the inhibition of PI3K $\gamma$  in C5a-induced pAKT (Ser473) in the RAW264.7 mouse macrophage cells (Evans et al., 2016) (Fig. 1C and D). The inhibitory activity of parsaclisib against PI3K $\beta$  in cells varied depending on the assay conditions utilized: the  $IC_{50}$  was  $>1000$  nM, based on measurements of constitutive pAKT (Ser473) in the In-Cell Western assay using the PC3 cell line (Wee et al., 2008); however, the  $IC_{50}$  was lower (approximately 30

JPET # 265538

nM), based on measurements of lysophosphatidic acid–induced pAKT (Ser473) in Western blots using PC3 cells (Lannutti et al., 2011), thus demonstrating  $\geq 30$ -fold selectivity of PI3K $\delta$  over PI3K $\beta$  (Fig. 1C and D). Idelalisib, evaluated in the same biochemical and cellular assays, demonstrated less selectivity for PI3K $\delta$  compared with piasclisib (Fig. 1B and D).

**Piasclisib Inhibits PI3K $\delta$  Functions in Primary Immune Cells.** PI3K $\delta$  is critical for B-cell survival and proliferation by functioning downstream of prosurvival receptors such as the BCR, B-cell activating factor receptor, and the interleukin-4 receptor, as well as costimulatory receptors such as CD40 and Toll-like receptors (Puri and Gold, 2012). Piasclisib inhibited the proliferation of human, dog, rat, and mouse primary B cells after activation of these receptors, with IC<sub>50</sub> values ranging from 0.2 to 1.7 nM (Supplemental Table 1). PI3K $\delta$  is also known to be critical for differentiation of Th1, Th2, and Th17 cells (Okkenhaug et al., 2006; Haylock-Jacobs et al., 2011; Kurebayashi et al., 2012; Roller et al., 2012; Steinbach et al., 2014) and cytokine production in memory T cells (Soond et al., 2010). Consistent with this, piasclisib demonstrated potent inhibitory activity against these PI3K $\delta$ -mediated functions in T cells (IC<sub>50</sub> values ranging from 0.2 to 1.5 nM) (Supplemental Table 1). Piasclisib was further evaluated for its potency in inhibiting anti-Fc $\epsilon$ R antibody–induced CD63 expression on basophils in human whole blood as previously described (Lannutti et al., 2011), demonstrating a mean IC<sub>50</sub> of approximately 2 nM (Supplemental Table 1).

Ablation of PI3K $\delta$  catalytic function using a p110 $\delta^{D910A/D910A}$  mouse model does not impact on CD3-induced T-cell proliferation in the presence of CD28 costimulation, suggesting that CD28 may use PI3K $\delta$ -independent pathways to enhance T-cell receptor signaling in p110 $\delta^{D910A/D910A}$ -expressing T cells (Okkenhaug et al., 2002; Okkenhaug et al., 2006). Consistent with these findings, we observed that piasclisib did not inhibit anti-CD3 or anti-CD3 plus anti-

JPET # 265538

CD28 antibody–induced proliferation of human T cells ( $IC_{50} >1000$  nM) and only modestly inhibited anti-CD28 antibody–induced T-cell proliferation ( $IC_{50} = 96$  nM) (Supplemental Table 1). Parsaclisib also did not inhibit interleukin-2–induced human natural killer cell proliferation, but was active in suppressing differentiation of naïve human T cells into a Th17, Th1, or Th2 phenotype and inhibiting functions of human memory T cells measured by cytokine production (Supplemental Table 1).

**Parsaclisib Inhibits Proliferation of MCL and DLBCL Cell Lines In Vitro and In Vivo.** The antiproliferative effect of parsaclisib on B-cell lymphoma cell lines was assessed using the [ $^3H$ ]-thymidine uptake assay. In the 4 MCL cell lines tested (Jeko-1, Mino, Rec-1, and JVM2), treatment with parsaclisib resulted in a maximal inhibition of 70 to 90%, with  $IC_{50}$  values  $\leq 10$  nM (Fig. 2A). Signaling studies in these cells showed that parsaclisib reduced the levels of constitutive pAKT (Ser473) and pFOXO1 with similar potencies (Fig. 2B). The level of FOXO1 phosphorylation was investigated, as it is a signaling event known to be downstream of AKT activation by PI3K in the regulation of cell proliferation (Fabre et al., 2005).

Among the 7 DLBCL cell lines (all germinal center B-cell–like subtype) that were evaluated for their sensitivity to parsaclisib in the proliferation assay, 4 (Pfeiffer, SU-DHL-5, SU-DHL-6, and WSU-NHL) were highly sensitive with  $IC_{50}$  values from 2 to 8 nM (Fig. 2C). The remaining 3 cell lines (SU-DHL-4, SU-DHL-8, and WILL-2) showed no sensitivity to parsaclisib, although the levels of pAKT (Ser473) and pFOXO1 in all 7 DLBCL cell lines were similarly reduced by compound treatment (Fig. 2D).

To determine if the broad antiproliferative effects seen with parsaclisib in vitro could also be observed in vivo, we utilized Pfeiffer (DLBCL) and Rec-1 (MCL) subcutaneous mouse xenograft models. Using pAKT (Ser473) as a pharmacodynamic marker of PI3K $\delta$  in Pfeiffer

JPET # 265538

xenograft tumors, pascalisib inhibited pAKT (Ser473) within 4 hours of a single oral administration, consistent with in vivo pascalisib activity (Supplemental Fig. 1A). Based on the pharmacokinetic properties of pascalisib in mice (Supplemental Fig. 1B), and the effect on pAKT levels in vivo, a dose range of 0.1 to 10 mg/kg b.i.d. for efficacy studies was chosen to maintain adequate levels of pascalisib over a 24-hour period. Pascalisib slowed Pfeiffer xenograft tumor growth in a dose-dependent manner, with significant tumor growth inhibition (TGI) occurring with 1 and 10 mg/kg b.i.d. dose levels (Fig. 3A). In each study, pascalisib was well tolerated as monitored by nonsignificant changes in body weight with treatment. Likewise, pascalisib significantly slowed Rec-1 xenograft tumor growth at each dose used (Fig. 3B). Pascalisib also showed additive effects with bendamustine, a cytotoxic alkylating chemotherapeutic agent for treating indolent B-cell malignancies, in the Pfeiffer and Rec-1 models (Fig. 3C and 3D), which provides translational evidence to support future clinical study of pascalisib plus bendamustine in patients with B-cell lymphoma.

**BET Inhibition Overcomes Insensitivity to Pascalisib-Mediated Growth Inhibition in DLBCL With MYC Dysregulation.** The insensitivity of the SU-DHL-4, SU-DHL-8, and WILL-2 cell lines to pascalisib was in stark contrast to the sensitivity of other lymphoma lines tested. Pascalisib reduced pAKT (Ser473) and pFOXO1 levels in SU-DHL-4, SU-DHL-8, and WILL-2 cells, yet did not inhibit their proliferation. One possible reason for this insensitivity to PI3K $\delta$  inhibition is aberrant expression of MYC as an overriding proliferative signal. Several reports have shown that MYC dysregulation may be an underlying mechanism for resistance to PI3K inhibition (Ilic et al., 2011; Liu et al., 2011). However, the role of MYC in the mechanism of resistance to PI3K $\delta$ -specific inhibition has not yet been determined. Both SU-DHL-8 and WILL-2 cells carry the t(8;22) chromosome translocation, resulting in *IgL-MYC* rearrangement

JPET # 265538

and presumably increased *MYC* transcription. While SU-DHL-4 cells have no *MYC*-associated translocation, they do express a high level of *MYC* protein (Schrader et al., 2012). Using Western blotting, the expression of *MYC* was barely detectable in the 4 parsacalisib-sensitive DLBCL cell lines (Pfeiffer, SU-DHL-5, SU-DHL-6, and WSU-NHL) compared with strong expression in the 3 parsacalisib-insensitive DLBCL cell lines (WILL-2, SU-DHL-4, and SU-DHL-8) (Fig. 4A).

The striking difference in *MYC* levels between parsacalisib-sensitive and -insensitive cell lines suggests that modulation of *MYC* levels may result in heightened sensitivity to PI3K $\delta$  inhibition. Bromodomain and extraterminal domain (BET) family of proteins are epigenetic modulators of gene expression that bind selectively to acetylated histone lysine residues and have been shown to stimulate growth of malignant B cells by promoting *MYC* expression. (Delmore et al., 2011; Boi et al., 2015). We tested SU-DHL-4, SU-DHL-8, and WILL-2 cells with the BET inhibitor INCB054329 (Stubbs et al., 2019). All 3 parsacalisib-insensitive DLBCL cell lines were sensitive to BET inhibition by INCB054329 in an in vitro proliferation assay (Fig. 4B). No synergistic or additive effects were observed between parsacalisib and INCB054329 in the same in vitro assay (data not shown). Concomitantly, the expression of *MYC* was reduced by INCB054329 in a dose-dependent manner (Fig. 4C). The potency of the inhibitory effect of INCB054329 on *MYC* expression appeared to be similar to that for the inhibitory effect on cell proliferation.

The ability of parsacalisib-insensitive cell lines to respond to BET inhibition with INCB054329 in vivo was tested in WILL-2 subcutaneous tumors. The effects of parsacalisib or INCB054329 on TGI were not statistically different compared with the vehicle control. However, the TGI resulting from the combination of both compounds at the same doses differed



JPET # 265538

significantly from each single-agent group and from the vehicle control. Importantly, all doses were well tolerated as monitored by nonsignificant changes in body weight with treatment. These data suggest that suppression of PI3K $\delta$  with piasclisib may enhance the sensitivity of lymphomas with *MYC* overexpression to BET inhibition with INCB054329 in vivo (Fig. 4D).

To understand the potential mechanism(s) behind this apparent synergy between PI3K $\delta$  and BET inhibition in the WILL-2 model, gene expression profiles in the tumors were analyzed by RNAseq. Based on a general linear model and hierarchical clustering of 5654 differentially expressed genes, the combination treatment of piasclisib and INCB054329 resulted in a distinct gene expression pattern when compared with either piasclisib or INCB054329 alone (Fig. 4E). In particular, gene set enrichment analyses showed strong suppression of *MYC*-associated genes (Delmore et al., 2011; Lampson et al., 2016) as well as an enrichment of a p53 pathway signature (Fig. 4F), indicating that simultaneous BET and PI3K $\delta$  inhibition can inhibit cell growth via several mechanisms in PI3K $\delta$  inhibitor-insensitive cells. Together, high expression of both *MYC* and p53 correlate with poor prognosis in DLBCL (Richardson et al., 2018). Importantly, of the 3363 genes differentially expressed following combination treatment of piasclisib and INCB054329, 2389 were uniquely regulated when compared with the single-agent groups (Supplemental Table 2). Genes showing significantly decreased expression with combination treatment versus vehicle included *CCR6*, *CCR2*, *CCR5*, *CCR1*, *CXCR2*, *CCL3L3*, and *CCL1* ( $P < 0.05$ ). This suggests that tumor cell networks mediated by chemokine and chemokine receptors could also be affected.

**Piasclisib Functions As an Immunomodulator and Inhibits Tumor Growth in the A20 Syngeneic Mouse Model for Lymphoma.** In addition to its direct antiproliferative activity through inhibition of intracellular signaling in malignant B cells and effect on chemokine and

JPET # 265538

chemokine receptor networks, we hypothesized that PI3K $\delta$  inhibition can potentially suppress tumor growth through modulation of regulatory and cytotoxic T cells within the B-cell lymphoma microenvironment. PI3K $\delta$  activity has been shown to be critical for the immunosuppressive function of Tregs (Patton et al., 2006). Inhibition of PI3K $\delta$  has also been suggested to delay terminal differentiation of CD8<sup>+</sup> T cells, and maintain memory phenotype, cytokine, and granzyme B production (Abu Eid et al., 2017). A syngeneic A20 lymphoma model was used to assess the effect of piasclisib on tumor growth through modulation of immune cells in a B-cell lymphoma microenvironment. A20 cells are relatively insensitive to piasclisib in an in vitro proliferation assay (IC<sub>50</sub> >3000 nM). However, treatment of Balb/c mice bearing the A20 murine lymphoma cells with piasclisib resulted in significant TGI (Fig. 5A).

In support of the observed antitumor effect of piasclisib in the A20 model, treatment with piasclisib reduced the percentage of Tregs (CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup>) in tumors and spleens (Fig. 5B; Supplemental Fig. 2A). In line with the decrease in Tregs, the ratio of CD4<sup>+</sup> and CD8<sup>+</sup> T cells to Tregs in spleens and tumors was increased by treatment with piasclisib (Fig. 5C and 5D). Because PI3K $\delta$  has been implicated in T-cell memory phenotype (Abu Eid et al., 2017), the effect of piasclisib on this subset of T cells in the A20 model was analyzed. Piasclisib treatment resulted in a decrease in the number of CD4<sup>+</sup>CD44<sup>high</sup> and CD8<sup>+</sup>CD44<sup>high</sup> T cells in both spleens and tumors (Fig. 5E and 5F; Supplemental Fig. 2B). Further analysis of the CD44<sup>high</sup> T-cell population, which is considered to be a marker for the activated/memory T cells, showed that PI3K $\delta$  inhibition by piasclisib increased the percentage of effector memory (CD44<sup>high</sup>CD62L<sup>low</sup>), but decreased the percentage of central memory (CD44<sup>high</sup>CD62L<sup>high</sup>) CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the spleens. The percentage of the tumor infiltrating central and effector memory cells was not affected by piasclisib (Supplemental Fig. 2C).

**Parsaclisib Is Associated With Reduced Hepatotoxicity.** We postulated that the liver toxicities observed with the first-generation PI3K $\delta$  inhibitors idelalisib, duvelisib, and INCB040093 are caused by off-target effects that can be linked to this class of molecules. The purine motif is identical within all 3 compounds and each contains a phenyl substituted bicyclic aryl core (Table 1). Parsaclisib is derived from a different scaffold consisting of a pyrazolopyrimidine in place of the purine, and a lactam substituted monocycle core (Table 1).

In 28-day repeat dose GLP safety studies of parsaclisib, no evidence of direct hepatotoxicity was observed in dogs or rats; in 8- and 9-day non-GLP rat studies, evidence of hepatotoxicity was observed, but only at very large multiples (>25-fold) of the exposures observed in patients administered a 20-mg, once-daily dose. Importantly, human clinical trials have also shown reduced clinically relevant, liver-related safety findings or adverse events (Forero-Torres et al., 2019) (Table 1), supporting our hypothesis that liver toxicities associated with first-generation PI3K $\delta$  inhibitors are the result of off-target effects, and that alternative molecules with a reduced potential for hepatotoxicity can be developed.

Umbralisib (TGR-1202) is another next-generation PI3K $\delta$  inhibitor. Like parsaclisib, only a small proportion of patients experienced liver-related toxicities in clinical studies (Burriss et al., 2018) (Table 1). The structure of umbralisib contains a phenyl substituted bicyclic aryl core but replaces the purine substituent with a pyrazolopyrimidine similar to parsaclisib (Table 1). Thus, based on the structure analysis and the corresponding preclinical and clinical safety study findings, we hypothesize that the off-target liver toxicity associated with the 3 first-generation PI3K $\delta$  inhibitors may be due to an untoward interaction involving the common purine substituent within these structures.

## DISCUSSION

We present the preclinical characterization of piasclisib, a structurally novel PI3K $\delta$  inhibitor, in clinical trials for the treatment of B-cell malignancies. The results demonstrate that piasclisib is a highly potent and selective PI3K $\delta$  inhibitor in various biochemical and cell-based assays, with reduced hepatotoxicity compared with first-generation PI3K $\delta$  inhibitors (which has limited their utility in the clinical setting). The first-generation PI3K $\delta$  inhibitors share a common purine constituent in their chemical structures. Piasclisib is the product of a discovery program aimed at investigating whether an alternative scaffold could circumvent the hepatotoxicity associated with first-generation PI3K $\delta$  inhibitors. Indeed, piasclisib has demonstrated minimal hepatotoxicity in preclinical and clinical studies. Therefore, we hypothesize that the hepatotoxicity associated with the first-generation PI3K $\delta$  inhibitors is structure-based rather than mechanism-based.

Consistent with the therapeutic potential of piasclisib for hematologic malignancies, proliferation of MCL and DLBCL cell lines in vitro and tumor growth in MCL and DLBCL xenograft models in vivo were potently inhibited by piasclisib. Piasclisib inhibited in vitro proliferation of 4 MCL cell lines and the growth of 1 MCL cell line (Rec-1) in a xenograft model. Signaling studies confirmed that the effect of piasclisib in these cells is through inhibition of PI3K-mediated pathways. In keeping with these preclinical results, a high ORR (67%) was achieved among patients receiving piasclisib for relapsed or refractory MCL in a recent phase 1/2 study (Forero-Torres et al., 2019). MCL is genetically characterized by the t(11;14) translocation that juxtaposes the proto-oncogene *CCND1*, which encodes cyclin D1 at chromosome 11, to the *IGH* gene, which encodes Ig heavy chain at chromosome 14. As a consequence, cyclin D1, which is not expressed in normal B cells, becomes constitutively

JPET # 265538

overexpressed. This genetic alteration is thought to be the primary event in MCL pathogenesis, probably by facilitating cell cycle deregulation at the G1-S phase transition (Jares et al., 2007). However, the AKT survival pathway is activated in MCL, particularly in the blastoid variants with the loss of phosphatase and tensin homologue expression (Rudelius et al., 2006). The MCL cell lines tested in this study contain the t(11;14) translocation, yet are highly sensitive to PI3K $\delta$  inhibition by piasclisib, suggesting that the PI3K $\delta$ /AKT signaling pathway is as critical as cyclin D1 overexpression for the development and/or survival of MCL.

Evidence suggests that PI3K $\delta$  signaling may also play a role in DLBCL pathogenesis. For example, a single mutation in the catalytic domain of PI3K $\delta$  maintained the level of pAKT after cytokine withdrawal in recombinant cells (Zhang et al., 2013). Likewise, chronic BCR signaling, which activates PI3K $\delta$ , might be a pathogenic mechanism in the activated B-cell–like subtype of DLBCL (Davis et al., 2010). We found that not all DLBCL cell lines are sensitive to PI3K $\delta$  inhibition despite inhibition of the PI3K signaling pathway by piasclisib. One similarity shared by the piasclisib-sensitive DLBCL cell lines is the presence of the t(14;18) chromosome translocation, which juxtaposes the *BCL2* gene on chromosome 18 to the *IGH* enhancer on chromosome 14, resulting in *BCL2* protein overexpression and inhibition of apoptosis (McDonnell et al., 1989). Our observations suggest that inhibition of the growth-/survival-promoting effects of PI3K signaling can override the anti-apoptotic effect of *BCL2* in these cells. Interestingly, the t(14;18) translocation frequency is about 15 to 30% in DLBCL and 85% in FL (Johnson et al., 2009), which is similar to the clinical response rate among patients with relapsed or refractory DLBCL (30%) and FL (71%) receiving piasclisib (Forero-Torres et al., 2019).

The piasclisib-insensitive cell lines tested all have exaggerated MYC expression, and MYC reduction by BET inhibitor treatment correlated closely with cell proliferation inhibition,

JPET # 265538

indicating that *MYC* dysregulation may be a driver of proliferation in these cells. Indeed, piasclisib combination with the BET inhibitor INCB054329 showed synergistic antitumor activity *in vivo*, demonstrating that insensitivity to PI3K $\delta$  inhibition by piasclisib may be overcome by *MYC*-targeting strategies such as BET inhibition (Delmore et al., 2011; Boi et al., 2015). The enhanced efficacy observed with combined PI3K $\delta$  and BET inhibition likely reflects enrichment of a p53 pathway gene expression profile, as well as repression of *MYC* transcriptional targets. Previous studies have established a dual mechanism of action for the anti-B-cell malignancy effect of PI3K $\delta$  inhibition: direct decrease of cell survival/proliferation as well as inhibition of chemokine production that aids retention of malignant B cells in protective tissue microenvironments. Clinically, PI3K $\delta$  inhibition has been shown to cause rapid lymph node shrinkage and transient lymphocytosis in patients with CLL. It is believed that PI3K $\delta$  functions to promote tumor cell connection with stroma cells through an intricate chemokine and chemokine receptor network (Hoellenriegel et al., 2011). We found that the expression of multiple chemokines and chemokine receptors was substantially decreased upon combination inhibition. Combining PI3K $\delta$  with BET inhibition may be useful in the clinic for treating DLBCL patients with high *MYC* expression levels with a suboptimal response to PI3K inhibition alone. This is based on the rationale that PI3K $\delta$  inhibition can break down the protective network of tumor cells by chemokine signaling, making the lymphoma more susceptible to direct growth/survival pathway inhibition by a BET inhibitor. The inhibitory effect of piasclisib on the chemokines and chemokine receptors is consistent with the current hypothesis. An additional approach to *MYC*-PI3K $\delta$  axis inhibition in these resistant tumors could involve inhibition of proviral integration site for Moloney murine leukemia virus (PIM) kinases, which occupy key nodes in signaling networks that are highly interconnected with those

JPET # 265538

mediated by PI3K $\delta$  (Forero-Torres et al., 2019). A previous study demonstrated additive or synergistic tumor-growth inhibitory effects of piasclisib in combination with the pan-proviral integration site for Moloney murine leukemia virus kinase inhibitor, INCB053914 (Koblish et al., 2018), and a clinical investigation of this combination has been opened (NCT03688152).

Based on previous findings that PI3K $\delta$  activity in different immune cells may have tumor protective functions (Ali et al., 2014), we explored whether piasclisib could function as an immune modulator in the tumor microenvironment by using the murine A20 model of lymphoma. Although A20 cells were not sensitive to piasclisib inhibition *in vitro*, tumor growth was suppressed in the murine A20 model, suggesting that part of the tumor inhibitory effect of piasclisib *in vivo* may be through immune modulation. Indeed, piasclisib reduced the number of Tregs in the tumors and spleens of treated mice. This result is consistent with recent clinical data showing that combined piasclisib and pembrolizumab (an anti-programmed cell death-1 antibody) significantly reduced the number of Tregs in patients with solid tumors (Kirkwood et al.). Tregs suppress antitumor immune responses by inhibiting cytotoxic T-cell activity in the tumor microenvironment (Chaudhary and Elkord, 2016), and it is therefore conceivable that immune activation may occur after piasclisib treatment. Interestingly, while preparing this report, a study was published supporting a critical role for PI3K $\delta$  in CLL pathogenesis through Tregs (Dong et al., 2019).

Memory CD8<sup>+</sup> T cells are superior mediators of antitumor immunity compared with terminally differentiated effector cells due to their greater proliferative potential (Gattinoni et al., 2005), but conflicting data exist on the role of PI3K $\delta$  in the regulation of T-cell differentiation. A recent study suggests that PI3K $\delta$  inhibition could delay terminal differentiation of CD8<sup>+</sup> T cells and maintain the memory phenotype and their ability to produce cytokines and granzyme B (Abu

JPET # 265538

Eid et al., 2017). However, in p110 $\delta^{D910A/D910A}$  mice, which lack functional PI3K $\delta$  catalytic activity, the expression of CD44 (a marker of memory T cells), was considerably reduced on CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Okkenhaug et al., 2002). Similarly, PI3K $\delta$  inactivation reduced the number of CD44<sup>high</sup>CD8<sup>+</sup> and CD44<sup>high</sup>CD4<sup>+</sup> T cells in the lymph nodes of mice bearing 4T1 or EL3 tumors (Ali et al., 2014). In the lymphoma A20 model, piasalisib treatment significantly reduced memory CD4 and CD8 T cells (CD44<sup>high</sup>) in the spleen and tumor, making it unlikely that T-cell differentiation plays a role in the mechanism of the observed antitumor activity of piasalisib.

In summary, piasalisib is a novel, highly potent, and selective PI3K $\delta$  inhibitor that has advanced into phase 2 clinical trials enrolling patients with hematologic B-cell malignancies. Preclinical validation has shown that piasalisib impedes B-cell lymphoma cell line growth in vitro and in vivo. Piasalisib also regulates the functions of B and T cells, theoretically making the tumor microenvironment less conducive to tumor growth. Additionally, insensitivity to piasalisib in DLBCL due to aberrant MYC overexpression may be overcome by combination with a BET inhibitor. Importantly, piasalisib demonstrated reduced hepatotoxicity in preclinical and clinical studies when compared with the first-generation compounds. Piasalisib is also distinct from other next-generation agents (e.g., umbralisib with a daily dose of 800 mg) in being administered as a 20-mg, once-daily dosing regimen, which has been shown to completely inhibit signaling through the PI3K $\delta$  pathway. Our results provide the mechanistic basis to fully support the ongoing efforts in the development of piasalisib for treating patients with B-cell malignancies. The potential immunomodulatory activity observed in these preclinical studies implies that piasalisib could have a broader application as a therapy outside of hematologic oncology.



JPET # 265538

## **Acknowledgments**

We would like to acknowledge Jordan Fridman and Kris Vaddi for their suggestions during the characterization of pascalisib. With this manuscript, we remember the contributions of our colleague Dr Yun-Long Li.

Medical writing assistance was provided by Abigail Marmont, PhD, CMPP, of Envision Pharma Group (Philadelphia, PA), and funded by Incyte Corporation.

JPET # 265538

### **Authorship contributions**

*Participated in research design:* Shin, Stubbs, Koblish, Yue, Soloviev, Gao, Diamond, Shuey, Yeleswaram, Combs, Newton, and Scherle.

*Conducted experiments:* Shin, Soloviev, K.H. Wang, Q. Wang, Gao, Feldman, Yang, Hall, Hansbury, O'Connor, Leffet, Collins, Katiyar, He, Waeltz, and Collier.

*Contributed new reagents or analytic tools:* Yue, Douty, Metcalf, Yao, and Combs.

*Performed data analysis:* Shin, Stubbs, Koblish, Soloviev, Y-L. Li, Y. Li, Liu, Burn, Covington, Diamond, Shuey, Roberts, Yeleswaram, Hollis, Metcalf, Yao, Huber, Combs, Newton, and Scherle.

*Wrote or contributed to the writing of the manuscript:* Shin, Stubbs, Koblish, Shuey, Combs, Newton, and Scherle.

JPET # 265538

## References

- Abu Eid R, Ahmad S, Lin Y, Webb M, Berrong Z, Shrimali R, Kumai T, Ananth S, Rodriguez PC, Celis E, Janik J, Mkrtychyan M, and Khleif SN (2017) Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K- $\delta$  inhibition. *Cancer Res* **77**:4135–4145.
- Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T, Maecker H, Friedman L, Turner M, Okkenhaug K, and Vanhaesebroeck B (2014) Inactivation of PI(3)K p110 $\delta$  breaks regulatory T-cell-mediated immune tolerance to cancer. *Nature* **510**:407–411.
- Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, and Bertoni F (2015) The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. *Clin Cancer Res* **21**:1628–1638.
- Burris HA, 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, and O'Connor OA (2018) Umbralisib, a novel PI3K $\delta$  and casein kinase-1 $\epsilon$  inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. *Lancet Oncol* **19**:486–496.
- Chaudhary B and Elkord E (2016) Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. *Vaccines* **4**:E28.
- Ciraolo E, Morello F, Hobbs RM, Wolf F, Marone R, Iezzi M, Lu X, Mengozzi G, Altruda F, Sorba G, Guan K, Pandolfi PP, Wymann MP, and Hirsch E (2010) Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. *Mol Biol Cell* **21**:704-711.
- Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, and Zelenetz AD (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. *Leuk Lymphoma* **56**:2779–2786.

JPET # 265538

- Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, and Staudt LM (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature* **463**:88–92.
- Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastiris E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, and Mitsiades CS (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell* **146**:904–917.
- Dong S, Harrington BK, Hu EY, Greene JT, Lehman AM, Tran M, Wasmuth RL, Long M, Muthusamy N, Brown JR, Johnson AJ, and Byrd JC (2019) PI3K p110 $\delta$  inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. *J Clin Invest* **129**:122–136.
- Evans CA, Liu T, Lescarbeau A, Nair SJ, Grenier L, Pradeilles JA, Glenadel Q, Tibbitts T, Rowley AM, DiNitto JP, Brophy EE, O'Hearn EL, Ali JA, Winkler DG, Goldstein SI, O'Hearn P, Martin CM, Hoyt JG, Soglia JR, Cheung C, Pink MM, Proctor JL, Palombella VJ, Tremblay MR, and Castro AC (2016) Discovery of a selective phosphoinositide-3-kinase (PI3K)- $\gamma$  inhibitor (IPI-549) as an immuno-oncology clinical candidate. *ACS Med Chem Lett* **7**:862–867.
- Fabre S, Lang V, Harriague J, Jobart A, Unterman TG, Trautmann A, and Bismuth G (2005) Stable activation of phosphatidylinositol 3-kinase in the T cell immunological synapse stimulates Akt signaling to FoxO1 nuclear exclusion and cell growth control. *J Immunol* **174**:4161–4171.
- Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, and Kahl B (2018) Duvelisib, an oral dual PI3K- $\delta$ ,  $\gamma$  inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. *Am J Hematol* **93**:1311–1317.

JPET # 265538

- Forero-Torres A, Ramchandren R, Yacoub A, Wertheim MS, Edenfield WJ, Caimi P, Gutierrez M, Akard L, Escobar C, Call J, Persky D, Iyer S, DeMarini DJ, Zhou L, Chen X, Dawkins F, and Phillips TJ (2019) Parsaclisib, a potent and highly selective PI3K $\delta$  inhibitor, in patients with relapsed or refractory B-cell malignancies. *Blood* **133**:1742–1752.
- Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, and Restifo NP (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8<sup>+</sup> T cells. *J Clin Invest* **115**:1616–1626.
- Gilead Sciences (2018) Zydelig (idelalisib) prescription information.  
[http://www.gilead.com/~media/Files/pdfs/medicines/oncology/zydelig/zydelig\\_pi.pdf](http://www.gilead.com/~media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf). Accessed September 26, 2019.
- Greenwell IB, Flowers CR, Blum KA, and Cohen JB (2017) Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. *Expert Rev Anticancer Ther* **17**:271–279.
- Haylock-Jacobs S, Comerford I, Bunting M, Kara E, Townley S, Klingler-Hoffmann M, Vanhaesebroeck B, Puri KD, and McColl SR (2011) PI3K $\delta$  drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. *J Autoimmun* **36**:278–287.
- Hers I (2007) Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3K $\alpha$  pathway. *Blood* **110**:4243–4252.
- Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, and Burger JA (2011) The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. *Blood* **118**:3603–3612.
- Ilic N, Utermark T, Widlund HR, and Roberts TM (2011) PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. *Proc Natl Acad Sci U S A* **108**:E699–708.

JPET # 265538

Jares P, Colomer D, and Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. *Nat Rev Cancer* **7**:750–762.

Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, and Horsman DE (2009) Lymphomas with concurrent *BCL2* and *MYC* translocations: the critical factors associated with survival. *Blood* **114**:2273–2279.

Kirkwood JM, Lannotti N, Cho D, O’Day S, Gibney G, Hodi S, Munster P, Hoyle P, Owens S, and al. e Effect of JAK/STAT or PI3K $\delta$  plus PD-1 inhibition on the tumor microenvironment: biomarker results from a phase 1b study in patients with advanced solid tumors. In: Proceedings of the 109th Annual Meeting of the American Association for Cancer Research; April 14–18, 2018; Chicago, Illinois. Abstract CT176.

Koblish H, Li YL, Shin N, Hall L, Wang Q, Wang K, Covington M, Marando C, Bowman K, Boer J, Burke K, Wynn R, Margulis A, Reuther GW, Lambert QT, Dostalík Roman V, Zhang K, Feng H, Xue CB, Diamond S, Hollis G, Yeleswaram S, Yao W, Huber R, Vaddi K, and Scherle P (2018) Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. *PLoS One* **13**:e0199108.

Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, Yamada T, Egami S, Hoshii T, Hirao A, Matsuda S, and Koyasu S (2012) PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of ROR $\gamma$ . *Cell Rep* **1**:360–373.

Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, and Brown JR (2016) Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. *Blood* **128**:195–203.

JPET # 265538

- Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, and Giese NA (2011) CAL-101, a p110 $\delta$  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. *Blood* **117**:591–594.
- Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, and Zhao JJ (2011) Oncogenic *PIK3CA*-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. *Nat Med* **17**:1116–1120.
- McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, and Korsmeyer SJ (1989) *bcl-2*-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. *Cell* **57**:79–88.
- Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJ, and Vanhaesebroeck B (2002) Impaired B and T cell antigen receptor signaling in p110 $\delta$  PI 3-kinase mutant mice. *Science* **297**:1031–1034.
- Okkenhaug K, Patton DT, Bilancio A, Garcon F, Rowan WC, and Vanhaesebroeck B (2006) The p110 $\delta$  isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. *J Immunol* **177**:5122–5128.
- Patton DT, Garden OA, Pearce WP, Clough LE, Monk CR, Leung E, Rowan WC, Sancho S, Walker LS, Vanhaesebroeck B, and Okkenhaug K (2006) Cutting edge: the phosphoinositide 3-kinase p110 $\delta$  is critical for the function of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells. *J Immunol* **177**:6598–6602.
- Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, and Barr PM (2018) Phase 1 study of the PI3K $\delta$  inhibitor INCB040093  $\pm$  JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. *Blood* **132**:293–306.
- Puri KD and Gold MR (2012) Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. *Front Immunol* **3**:256.

JPET # 265538

- Richardson A, Zhang D, Woodroof J, and Cui W (2018) p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status. *Hum Pathol* **86**:21–31.
- Roller A, Perino A, Dapavo P, Soro E, Okkenhaug K, Hirsch E, and Ji H (2012) Blockade of phosphatidylinositol 3-kinase PI3K $\delta$  or PI3K $\gamma$  reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis. *J Immunol* **189**:4612–4620.
- Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, Quintanilla-Martinez L, and Raffeld M (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. *Blood* **108**:1668–1676.
- Schrader A, Bentink S, Spang R, Lenze D, Hummel M, Kuo M, Arrand JR, Murray PG, Trümper L, Kube D, and Vockerodt M (2012) High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. *Int J Cancer* **131**:E348–361.
- Shin N, Li YL, Mei S, Wang KH, Hall L, Katiyar K, Wang Q, Yang G, Rumberger B, Leffet L, He X, Rupar M, Bowman K, Favata M, Li J, Liu M, Li Y, Covington M, Koblisch H, Soloviev M, Shuey D, Burn T, Diamond S, Fridman J, Combs A, Yao W, Yeleswaram S, Hollis G, Vaddi K, Huber R, Newton R, and Scherle P (2018) INCB040093 is a novel PI3K $\delta$  inhibitor for the treatment of B cell lymphoid malignancies. *J Pharmacol Exp Ther* **364**:120–130.
- Soond DR, Bjorgo E, Moltu K, Dale VQ, Patton DT, Torgersen KM, Galleway F, Twomey B, Clark J, Gaston JS, Tasken K, Bunyard P, and Okkenhaug K (2010) PI3K p110 $\delta$  regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. *Blood* **115**:2203–2213.
- Steinbach EC, Kobayashi T, Russo SM, Sheikh SZ, Gipson GR, Kennedy ST, Uno JK, Mishima Y, Borst LB, Liu B, Herfarth H, Ting JP, Sartor RB, and Plevy SE (2014) Innate PI3K p110 $\delta$  regulates Th1/Th17 development and microbiota-dependent colitis. *J Immunol* **192**:3958–3968.
- Stubbs MC, Burn TC, Sparks R, Maduskuie T, Diamond S, Rupar M, Wen X, Volgina A, Zolotarjova N, Waelz P, Favata M, Jalluri R, Liu H, Liu XM, Li J, Collins R, Falahatpisheh N, Polam P,



JPET # 265538

- DiMatteo D, Feldman P, Dostalík V, Thekkat P, Gardiner C, He X, Li Y, Covington M, Wynn R, Ruggeri B, Yeleswaram S, Xue CB, Yao W, Combs AP, Huber R, Hollis G, Scherle P, and Liu PCC (2019) The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies. *Clin Cancer Res* **25**:300–311.
- Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, and Lengauer C (2008) PTEN-deficient cancers depend on PIK3CB. *Proc Natl Acad Sci U S A* **105**:13057–13062.
- Whyte DB and Holbeck SL (2006) Correlation of *PIK3Ca* mutations with gene expression and drug sensitivity in NCI-60 cell lines. *Biochem Biophys Res Commun* **340**:469–475.
- Yue EW, Li Y-L, Douty B, He C, Mei S, Wayland B, Maduskuie T, Falahatpisheh N, Sparks RB, Padmaja P, Zhu W, Glenn J, Feng H, Zhang K, Li Y, He X, Katiya K, Covington M, Feldman P, Shin N, Wang K, Diamond S, Li Y, Koblisch H, Hall L, Scherle P, Yeleswaram S, Xue C-B, Metcalf B, Combs AP, and Yao W (2019) INCB050465 (parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-kinase delta (PI3K $\delta$ ). *ACS Med Chem Lett* **10**:1554–1560.
- Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, and Dave SS (2013) Genetic heterogeneity of diffuse large B-cell lymphoma. *Proc Natl Acad Sci U S A* **110**:1398–1403.

JPET # 265538

## Footnotes

**<sup>a</sup>Financial support:** This work was supported by Incyte Corporation, Wilmington, Delaware.

<sup>1</sup>Current affiliations: A. C. and P. S., Prelude Therapeutics, Inc., Wilmington, Delaware; R. H., Third Rock Ventures, Boston, Massachusetts; B. M., private consultant, Moraga, California; P. C. C. L., Kymera Therapeutics, Cambridge, Massachusetts.

JPET # 265538

## Legends for Figures

**Fig. 1.** Parsaclisib chemical structure and activity against class 1 PI3K. (A) Chemical structure of parsaclisib [((R)-4(3-((S)-1-(4-amino-3-methyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one)]. (B) Enzyme-inhibitory activity of parsaclisib at 1 mM concentration of ATP against different members of the human class 1 PI3K family ( $n \geq 3$ ). Idelalisib was tested in the same assays for comparison purposes. (C) Parsaclisib activity against PI3K $\alpha$ , PI3K $\beta$ , PI3K $\delta$ , and PI3K $\gamma$ -mediated signaling in cells by Western blotting. pAKT (Ser473) was induced by platelet-derived growth factor (PDGF), lysophosphatidic acid (LPA), anti-IgM and C5a in NIH3T3, PC-3, Ramos, and RAW264.7 cells, respectively, for PI3K $\alpha$ -, PI3K $\beta$ -, PI3K $\delta$ -, and PI3K $\gamma$ -mediated signaling. The levels of pAKT (Ser473) and total AKT were measured by Western blotting. The data are representative of 2 independent experiments. (D) The activities of parsaclisib and idelalisib against PI3K $\alpha$ -, PI3K $\beta$ -, PI3K $\delta$ -, and PI3K $\gamma$ -mediated signaling measured directly in cells. Constitutive levels of pAKT (Ser473) in SKOV-3 and PC-3 cells measured by In-Cell Western imaging were used to represent PI3K $\alpha$  and PI3K $\beta$  activities, respectively. PI3K $\gamma$  activity in RAW264.7 cells was measured by the level of pAKT (Ser473) induced by C5a and detected with In-Cell Western imaging. PI3K $\delta$  activity in Ramos cells were measured by the level of pAKT (Ser473) induced by anti-IgM and detected with fluorescence-activated cell sorting (FACS) analysis ( $n \geq 3$ ). Idelalisib was tested in the same assays for comparison purposes.

**Fig. 2.** Parsaclisib inhibits proliferation and constitutive PI3K signaling in MCL and DLBCL cell lines in vitro. (A) Jeko-1, Mino, JVM2, and Rec-1 cells (MCL) were cultured in growth medium for 4 days in the presence of different concentrations of parsaclisib and then pulsed with

JPET # 265538

[<sup>3</sup>H]thymidine overnight. Incorporated radioactivity was counted as measurement of cell growth. Each curve is a representative and value average of multiple individual experiments ( $n = 5$  for Rec-1,  $n = 5$  for Mino,  $n = 5$  for JVM2, and  $n = 3$  for Jeko-1). (B) The MCL cell lines in growth medium were treated with different concentrations of piasclisib for 2 hours. The levels of pAKT (Ser473) and pFOXO1 (T24) in the total cell lysates were then measured by Western blotting. Actin levels in the cell lysates was used as loading control. These data are representative of 2 independent experiments. (C) Pfeiffer, SU-DHL-5, SU-DHL-6, WSU-NHL, SU-DHL-4, SU-DHL-8, and WILL-2 cells (DLBCL, all germinal center B-cell-like subtype) were cultured in growth medium for 4 days in the presence of different concentrations of piasclisib and then pulsed with [<sup>3</sup>H]thymidine overnight. Incorporated radioactivity was counted as measurement of cell growth. Each curve is a representative and value average of multiple individual experiments ( $n = 9$  for Pfeiffer,  $n = 4$  for SU-DHL-5,  $n = 6$  for SU-DHL-6,  $n = 4$  for WSU-NHL,  $n = 3$  for SU-DHL-4,  $n = 3$  for SU-DHL-8, and  $n = 3$  for WILL-2). (D) The DLBCL cells in growth medium were treated with different concentrations of piasclisib for 2 hours. The levels of pAKT (Ser473) and pFOXO1 (T24) in the total cell lysates were then measured by Western blotting. Actin levels in the cell lysates was used as loading control. The data are representative of 2 independent experiments.

**Fig. 3.** Piasclisib is active as a single agent and in combination with standard-of-care chemotherapy against tumor growth in the Pfeiffer and Rec-1 models for DLBCL and MCL. Efficacy of piasclisib in the Pfeiffer (A) and Rec-1 (B) subcutaneous xenograft models. Efficacy of piasclisib in combination with bendamustine in the Pfeiffer (C) and Rec-1 (D)

JPET # 265538

subcutaneous xenograft models. The difference in percentage tumor growth inhibition (TGI) was analyzed by *t* test. b.i.d., twice daily; q.w., once weekly.

**Fig. 4.** Insensitivity to parasclisib in DLBCL cells with high MYC expression can be overcome by BET inhibition. (A) Comparison of MYC expression in 4 parasclisib-sensitive DLBCL cell lines (Pfeiffer, SU-DHL-5, SU-DHL-6, and WSU-NHL) and 3 parasclisib-insensitive DLBCL cell lines (WILL-2, SU-DHL-4, and SU-DHL-8). (B) [<sup>3</sup>H]-thymidine uptake proliferation assays were performed on the 3 parasclisib-insensitive DLBCL cell lines (SU-DHL-4, SU-DHL-8, and WILL-2) treated with the BET inhibitor INCB054329. The data represent an average of 3 independent experiments. (C) Western blot composite showing dose-dependent reduction of MYC levels by INCB054329 in the 3 parasclisib-insensitive DLBCL cell lines, SU-DHL-4, SU-DHL-8, and WILL-2. (D) Growth of WILL-2 tumor in mice dosed with parasclisib and INCB054329. The difference in percentage of tumor growth inhibition (TGI) was analyzed by *t* test. (E) Heat map of differentially expressed genes showing distinct expression effects by each treatment (INCB054329, parasclisib, or both compounds in combination). The list of 5654 differentially expressed genes was generated based on a general linear model and hierarchical clustering of gene expression with false discovery rate (FDR) *P* value  $\leq 0.05$ . (F) Gene Set Enrichment Analysis signatures highlighting coordinated differential expression of gene sets that significantly enriched or decreased in WILL-2 tumor samples treated with combination of parasclisib and INCB054329 versus vehicle control with *P* < 0.01. b.i.d., twice daily.

**Fig. 5.** Parasclisib is efficacious in reducing tumor growth in the A20 model of lymphoma. (A) Growth of A20 tumor in female Balb/c mice with or without parasclisib treatment. The treatment

JPET # 265538






of the tumor-bearing mice started 7 to 24 days after tumor inoculation. (B) Effect of pascalisib on the percentage of regulatory T cells (Tregs) (CD25<sup>+</sup>FOXP3<sup>+</sup>CD4<sup>+</sup>) in the CD4<sup>+</sup> T cells isolated from spleens and tumors in the A20 model. Effect of pascalisib on the ratio of CD4<sup>+</sup> and CD8<sup>+</sup> T cells versus Tregs in spleens (C) and tumors (D) of the A20 model. Effect of pascalisib on the percentage of memory/activated cells (CD44<sup>+</sup>) within the CD4<sup>+</sup> (E) and CD8<sup>+</sup> (F) T-cell subpopulations in spleens and tumors of the A20 model. In B, C, D, E, and F, the mice were treated with pascalisib at 10 mg/kg once daily or vehicle control for 7 days before being euthanized for collection and processing of tumors and spleens for fluorescence-activated cell sorting analysis.

JPET # 265538

## Tables

TABLE 1

Clinically observed hepatotoxicity for PI3K $\delta$  inhibitors

Idelalisib	Duvelisib	INCB040093	Umbralisib	Parsaclisib
				
ALT/AST elevation: Any: 39–50% ≥Grade 3: 9–19% Fatal and/or serious hepatotoxicity: 16–18% <sup>a</sup>	ALT/AST elevation: Any: 39% ≥Grade 3: 20% <sup>b</sup>	ALT/AST elevation: Any: 33% ≥Grade 3: 20% <sup>c</sup>	ALT/AST elevation: Any: 7% ≥Grade 3: 3% <sup>d</sup>	ALT/AST elevation: Any 28–29% ≥Grade 3: 1–3% <sup>e</sup>

<sup>a</sup> From reference (Gilead Sciences); <sup>b</sup> From reference (Flinn et al., 2018); <sup>c</sup> From reference

(Phillips et al., 2018); <sup>d</sup> From reference (Burriss et al., 2018); <sup>e</sup> From reference (Forero-Torres et al., 2019).

ALT, alanine transaminase; AST, aspartate transaminase.

JPET # 265538

**Figures**




Figure 1



JPET # 265538




Figure 2

JPET # 265538




Figure 3




Figure 4

JPET # 265538




Figure 5

## Supplemental Materials

### **Parsaclisib Is a Next-Generation PI3K $\delta$ Inhibitor With Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy**

Niu Shin, Matthew Stubbs, Holly Koblish, Eddy W. Yue, Maxim Soloviev, Brent Douty, Kathy He Wang, Qian Wang, Mingming Gao, Patricia Feldman, Gengjie Yang, Leslie Hall, Michael Hansbury, Sybil O'Connor, Lynn Leffet, Robert Collins, Kamna Katiyar, Xin He, Paul Waeltz, Paul Collier, Jin Lu, Yun-Long Li, Yanlong Li, Phillip C.C. Liu\*, Timothy Burn, Maryanne Covington, Sharon Diamond, Dana Shuey, Alan Roberts, Swamy Yeleswaram, Greg Hollis, Brian Metcalf\*, Wenqing Yao, Reid Huber\*, Andrew Combs\*, Robert Newton, and Peggy Scherle\*

*Incyte Research Institute, Wilmington, Delaware.*

\*Current affiliation: A. C. and P. S., Prelude Therapeutics, Inc., Wilmington, Delaware; R. H., Third Rock Ventures, Boston, Massachusetts; B. M., private consultant, Moraga, California; P. C. C. L., Kymera Therapeutics, Cambridge, Massachusetts.

## Supplementary Methods

### Chemicals, antibodies, and cell lines

Dimethylacetamide (#271012), methylcellulose (#M7027), and lysophosphatidic acid (#151884) were purchased from Sigma (St Louis, Missouri). Bendamustine (#3543-75-7) was purchased from Chemscene (Monmouth Junction, New Jersey). Platelet-derived growth factor (#120-HD) and complement component C5a (#2150-C5) were purchased from R&D Systems (Minneapolis, Minnesota). The anti-CD4-Alexa Fluor 700 (#557922), anti-CD8-FITC (#347313), anti-CD44-APC-Cy7 (#506568), anti-FOXP3-PE (#560046), and anti-CD62L-BUV737 (#741843) antibodies for fluorescence-activated cell sorting (FACS) analysis were purchased from BD Biosciences (Franklin Lakes, New Jersey). The anti-pAKT (Ser 473) antibody (#9271) for Western blotting and anti-pAKT (Ser 473)-Fluor 488 antibody (#4071) for FACS were purchased from Cell Signaling Technology (Danvers, Massachusetts). The anti-IgM antibody (#14-9998-82) for B-cell receptor stimulation was purchased from Invitrogen (Carlsbad, California). The anti-pAKT (Ser 473, #1861786), anti-AKT (#1861776), anti-rabbit (Dylight 800, #1861741), and anti-mouse (Dylight 680, #1861740) antibodies for In-Cell Western analysis were purchased from Thermo Scientific (Waltham, Massachusetts). A20 (#TIB-208), Pfeiffer (#CRL-2632), SU-DHL-6 (#CRL-2959), Jeko-1 (#CRL-3006), Mino (#CRL-300), Rec-1 (#CRL-3004), JVM2 (#CRL-3002), RAW264.7 (#TIB-71), Ramos (#CRL-1596), SKOV-3 (#HTB77), and PC-3 (#CRL-1435) cell lines were purchased from ATCC (Manassas, Virginia). SU-DHL-5 (#ACC 571), WILL-2 (#ACC 652), WSU-NHL (#ACC 58), SU-DHL-4 (#ACC 495), and SU-DHL-8 (#ACC 573) cell lines were obtained from DSMZ (Braunschweig, Germany).

SUPPLEMENTAL TABLE 1

Inhibitory activities of piasclisib against PI3K $\delta$ -mediated functions in cells

Primary cell	Stimulants	Response	IC <sub>50</sub> $\pm$ S.D. (nM)	N
Human B	Anti-human IgM Ab	Proliferation <sup>a</sup>	0.21 $\pm$ 0.12	4
Human B	LPS + IL-4	Proliferation	0.73 $\pm$ 0.59	6
Human B	IL-4	Proliferation	0.47 $\pm$ 0.14	6
Human B	LPS	Proliferation	0.15 $\pm$ 0.02	3
Human B	CD40 ligand	Proliferation	0.72 $\pm$ 0.22	4
Human B	Anti-human CD40 Ab	Proliferation	0.42 $\pm$ 0.21	5
Human B	IL-6	Proliferation	0.59 $\pm$ 0.42	3
Human B	BAFF	Proliferation	0.53 $\pm$ 0.18	7
Mouse B	LPS + mIL-4 or mBAFF	Proliferation	0.37 $\pm$ 0.31	5
Rat B	LPS + rIL-4 + anti-rat IgM	Proliferation	1.19 $\pm$ 1.20	3
Dog B	Anti-canine IgM Ab	Proliferation	1.72	2
Human T	Anti-human CD3 Ab	Proliferation	>1000	4
Human T	Anti-human CD28 Ab	Proliferation	96.63 $\pm$ 52.93	3
Human T	Anti-human CD28 and CD3 Ab	Proliferation	>330	3
Human naïve T	Th17 differentiation	IL-17 production	0.90 $\pm$ 0.68	11
Human naïve T	Th17 differentiation	IFN- $\gamma$ production	0.65 $\pm$ 0.48	9
Human naïve T	Th1 differentiation	IFN- $\gamma$ production	0.73 $\pm$ 0.93	6
Human naïve T	Th2 differentiation	IL-13 production	0.26	2
Human memory T	Anti-CD3 Ab	IL-17 production	0.98	2
Human memory T	Anti-CD3 Ab	IFN- $\gamma$ production	0.97	2
Human memory T	Anti-CD3 + anti-CD28 + anti-CD2 Ab	IL-17 production	1.12 $\pm$ 0.49	5
Human memory T	Anti-CD3 + anti-CD28 + anti-CD2 Ab	IFN- $\gamma$ production	1.45 $\pm$ 1.49	4
Human NK	Human IL-2	Proliferation	>1000	2
Human basophil <sup>b</sup>	Anti-FcR	CD63 expression	1.96 $\pm$ 1.37	5


<sup>a</sup> Proliferation determined by <sup>3</sup>H-thymidine uptake; <sup>b</sup> The assay was conducted in the presence of whole blood. LPS, lipopolysaccharide.

SUPPLEMENTAL TABLE 2

Analysis of RNA sequencing data from the WILL-2 xenograft model. Please refer to separate Excel document



**Supplemental Fig. 1.** Parsaclisib is active against tumor growth in the Pfeiffer model for DLBCL. (A) Western blotting analysis showing reduction in the pAKT (Ser 473) level in the Pfeiffer xenograft tumors 4 hours after dosing with parsaclisib at 0.5 mg/kg and 1 mg/kg. (B) Pharmacokinetic analysis showing parsaclisib exposure level in the plasma of the mice bearing the Pfeiffer tumor. The IC<sub>90</sub> was covered for more than 8 hours when the compound was dosed at 1 mg/kg or 10 mg/kg.



**Supplemental Fig. 2.** Effect of piasalisib on different T-cell populations in the A20 model of lymphoma. Gating strategy in fluorescence-activated cell sorting (FACS) analysis of piasalisib treatment-induced changes in Tregs (CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup>) (A) and memory (CD44<sup>+</sup>) CD4<sup>+</sup> and CD8<sup>+</sup> T-cell populations (B). (C) Effect of piasalisib on the central memory (CD44<sup>+</sup>CD62L<sup>high</sup>) and effector memory (CD44<sup>+</sup>CD62L<sup>low</sup>) CD4<sup>+</sup> and CD8<sup>+</sup> T cells in spleens and tumors of the A20 model. In these studies, the mice were treated with piasalisib at 10 mg/kg once daily or vehicle control for 7 days before being euthanized for collection and processing of tumors and spleens for FACS analysis.

